Construction of Chimeric Tumor Suppressor p53 Resistant to the Dominant-Negative Interaction with p53 Mutants

被引:0
|
作者
V. P. Almazov
A. A. Morgunkova
V. N. Kalinin
B. P. Kopnin
V. S. Prasolov
P. M. Chumakov
机构
[1] Russian Academy of Sciences,Engelhardt Institute of Molecular Biology
[2] Russian Academy of Medical Sciences,Medical Genetic Research Center
[3] Russian Academy of Medical Sciences,Institute of Carcinogenesis, Blokhin Cancer Research Center
来源
Molecular Biology | 2002年 / 36卷
关键词
tumor suppressor p53; transcriptional activation; chimeric protein; protein oligomerization;
D O I
暂无
中图分类号
学科分类号
摘要
A chimeric p53 cDNA was constructed so that the fragment coding for 39 residues of the chicken p53 tetramerization domain replaced the corresponding region of human p53. The chimeric cDNA substantially inhibited the colony-forming ability of transfected human and mouse cells, suggesting a suppressor potential of its product. The chimeric p53 activated promoters containing p53-responsive elements. In contrast to wild-type human p53, the chimeric p53 remained capable of transcription activation in the presence of a dominant-negative mutant p53-His175. This makes the chimeric p53 a convenient model for elaborating gene therapy protocols for tumors with dominant-negative p53 forms. The chimeric p53 may be used to study the role of transdominance of p53 mutants in carcinogenesis and the interactions of p53 with related transcription factors (p73, p63).
引用
收藏
页码:522 / 527
页数:5
相关论文
共 50 条
  • [1] Construction of chimeric tumor suppressor p53 resistant to the dominant-negative interaction with p53 mutants
    Almazov, VP
    Morgunkova, AA
    Kalinin, VN
    Kopnin, BP
    Prasolov, VS
    Chumakov, PM
    [J]. MOLECULAR BIOLOGY, 2002, 36 (04) : 522 - 527
  • [2] Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma
    Sakuragi, N
    Hirai, A
    Tada, M
    Yamada, H
    Yamamoto, R
    Fujimoto, S
    Moriuchi, T
    [J]. GYNECOLOGIC ONCOLOGY, 2001, 83 (03) : 485 - 490
  • [3] p53 tetramerization: at the center of the dominant-negative effect of mutant p53
    Gencel-Augusto, Jovanka
    Lozano, Guillermina
    [J]. GENES & DEVELOPMENT, 2020, 34 (17-18) : 1128 - 1146
  • [4] Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme
    Marutani, M
    Tonoki, H
    Tada, M
    Takahashi, M
    Kashiwazaki, H
    Hida, Y
    Hamada, J
    Asaka, M
    Moriuchi, T
    [J]. CANCER RESEARCH, 1999, 59 (19) : 4765 - 4769
  • [5] Dominant-negative p53 mutations in rheumatoid arthritis
    Han, ZN
    Boyle, DL
    Shi, Y
    Green, DR
    Firestein, GS
    [J]. ARTHRITIS AND RHEUMATISM, 1999, 42 (06): : 1088 - 1092
  • [6] Functional characterization of p53β and p53γ, two isoforms of the tumor suppressor p53
    Graupner, Vilma
    Schulze-Osthoff, Klaus
    Essmann, Frank
    Jaenicke, Reiner U.
    [J]. CELL CYCLE, 2009, 8 (08) : 1238 - 1248
  • [7] DOMINANT-NEGATIVE AGGREGATION OF P53 AS A NOVEL MECHANISM OF TUMOUR SUPPRESSOR GENE INACTIVATION
    Xu, J.
    Reumers, J.
    Couceiro, J.
    Rousseau, F.
    Schymkowitz, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S44 - S44
  • [8] Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer
    Sakuragi, N
    Watari, H
    Ebina, Y
    Yamamoto, R
    Steiner, E
    Koelbl, H
    Yano, M
    Tada, M
    Moriuchi, T
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (04) : 514 - 519
  • [9] In vitro analysis of the dominant negative effect of p53 mutants
    Chène, P
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1998, 281 (02) : 205 - 209
  • [10] Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide
    Bernal, Federico
    Tyler, Andrew F.
    Korsmeyer, Stanley J.
    Walensky, Loren D.
    Verdine, Gregory L.
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2007, 129 (09) : 2456 - +